nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—ADORA2A—NGF-independant TRKA activation—NTRK2—peripheral nervous system neoplasm	0.0425	0.18	CbGpPWpGaD
Regadenoson—ADORA2A—Activation of TRKA receptors—NTRK2—peripheral nervous system neoplasm	0.0367	0.156	CbGpPWpGaD
Regadenoson—ADORA2A—NGF-independant TRKA activation—NTRK1—peripheral nervous system neoplasm	0.0346	0.147	CbGpPWpGaD
Regadenoson—ADORA2A—Activation of TRKA receptors—NTRK1—peripheral nervous system neoplasm	0.0299	0.127	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.0252	0.107	CbGpPWpGaD
Regadenoson—ADORA2A—Monoamine Transport—TH—peripheral nervous system neoplasm	0.00882	0.0374	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.00852	0.0361	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—ALK—peripheral nervous system neoplasm	0.00671	0.522	CrCbGaD
Regadenoson—Adenosine triphosphate—AKT1—peripheral nervous system neoplasm	0.00524	0.407	CrCbGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.0047	0.0199	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00296	0.0125	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.00244	0.0103	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00225	0.00953	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NTRK2—peripheral nervous system neoplasm	0.00217	0.00919	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00216	0.00914	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.00203	0.00859	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.0018	0.00764	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NTRK1—peripheral nervous system neoplasm	0.00177	0.00749	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NTRK2—peripheral nervous system neoplasm	0.00167	0.00707	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NTRK1—peripheral nervous system neoplasm	0.00136	0.00576	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.00133	0.00563	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00127	0.00539	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00116	0.00489	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTPN11—peripheral nervous system neoplasm	0.00113	0.00478	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00111	0.00469	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00101	0.00428	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000964	0.00408	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—ABCB1—peripheral nervous system neoplasm	0.000914	0.0711	CrCbGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—peripheral nervous system neoplasm	0.000891	0.00378	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000884	0.00375	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000875	0.00371	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	0.000867	0.00367	CbGpPWpGaD
Regadenoson—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.000864	0.00115	CcSEcCtD
Regadenoson—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000864	0.00115	CcSEcCtD
Regadenoson—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000862	0.00115	CcSEcCtD
Regadenoson—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000862	0.00115	CcSEcCtD
Regadenoson—Hypotension—Vincristine—peripheral nervous system neoplasm	0.00086	0.00114	CcSEcCtD
Regadenoson—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.000857	0.00114	CcSEcCtD
Regadenoson—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000851	0.00113	CcSEcCtD
Regadenoson—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000851	0.00113	CcSEcCtD
Regadenoson—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.00085	0.00113	CcSEcCtD
Regadenoson—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000849	0.00113	CcSEcCtD
Regadenoson—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.000849	0.00113	CcSEcCtD
Regadenoson—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000849	0.00113	CcSEcCtD
Regadenoson—Ill-defined disorder—Etoposide—peripheral nervous system neoplasm	0.000847	0.00113	CcSEcCtD
Regadenoson—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000846	0.00113	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000843	0.00112	CcSEcCtD
Regadenoson—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000842	0.00112	CcSEcCtD
Regadenoson—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00084	0.00112	CcSEcCtD
Regadenoson—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000839	0.00112	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000838	0.00112	CcSEcCtD
Regadenoson—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000833	0.00111	CcSEcCtD
Regadenoson—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000833	0.00111	CcSEcCtD
Regadenoson—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000832	0.00111	CcSEcCtD
Regadenoson—Renal impairment—Doxorubicin—peripheral nervous system neoplasm	0.000827	0.0011	CcSEcCtD
Regadenoson—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.000826	0.0011	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000824	0.0011	CcSEcCtD
Regadenoson—Malaise—Etoposide—peripheral nervous system neoplasm	0.000824	0.0011	CcSEcCtD
Regadenoson—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000817	0.00109	CcSEcCtD
Regadenoson—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000814	0.00108	CcSEcCtD
Regadenoson—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000814	0.00108	CcSEcCtD
Regadenoson—Cardiac arrest—Epirubicin—peripheral nervous system neoplasm	0.000808	0.00108	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000808	0.00342	CbGpPWpGaD
Regadenoson—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000808	0.00108	CcSEcCtD
Regadenoson—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000803	0.00107	CcSEcCtD
Regadenoson—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000803	0.00107	CcSEcCtD
Regadenoson—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000801	0.00107	CcSEcCtD
Regadenoson—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000801	0.00107	CcSEcCtD
Regadenoson—Rash—Topotecan—peripheral nervous system neoplasm	0.000801	0.00107	CcSEcCtD
Regadenoson—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.0008	0.00107	CcSEcCtD
Regadenoson—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000798	0.00106	CcSEcCtD
Regadenoson—Cough—Etoposide—peripheral nervous system neoplasm	0.000797	0.00106	CcSEcCtD
Regadenoson—Headache—Topotecan—peripheral nervous system neoplasm	0.000796	0.00106	CcSEcCtD
Regadenoson—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000794	0.00106	CcSEcCtD
Regadenoson—Rash—Tretinoin—peripheral nervous system neoplasm	0.000794	0.00106	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000794	0.00106	CcSEcCtD
Regadenoson—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000794	0.00106	CcSEcCtD
Regadenoson—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000794	0.00106	CcSEcCtD
Regadenoson—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000794	0.00106	CcSEcCtD
Regadenoson—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000791	0.00105	CcSEcCtD
Regadenoson—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000791	0.00105	CcSEcCtD
Regadenoson—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.00079	0.00105	CcSEcCtD
Regadenoson—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000789	0.00105	CcSEcCtD
Regadenoson—Headache—Tretinoin—peripheral nervous system neoplasm	0.000789	0.00105	CcSEcCtD
Regadenoson—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000789	0.00105	CcSEcCtD
Regadenoson—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000787	0.00105	CcSEcCtD
Regadenoson—Pain—Vincristine—peripheral nervous system neoplasm	0.000787	0.00105	CcSEcCtD
Regadenoson—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000787	0.00105	CcSEcCtD
Regadenoson—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000787	0.00105	CcSEcCtD
Regadenoson—Rash—Melphalan—peripheral nervous system neoplasm	0.000784	0.00104	CcSEcCtD
Regadenoson—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000783	0.00104	CcSEcCtD
Regadenoson—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000781	0.00104	CcSEcCtD
Regadenoson—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000778	0.00104	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000772	0.00103	CcSEcCtD
Regadenoson—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000768	0.00102	CcSEcCtD
Regadenoson—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.00076	0.00101	CcSEcCtD
Regadenoson—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000759	0.00101	CcSEcCtD
Regadenoson—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000759	0.00101	CcSEcCtD
Regadenoson—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000755	0.00101	CcSEcCtD
Regadenoson—Nausea—Topotecan—peripheral nervous system neoplasm	0.000754	0.001	CcSEcCtD
Regadenoson—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000752	0.001	CcSEcCtD
Regadenoson—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000748	0.000997	CcSEcCtD
Regadenoson—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000748	0.000997	CcSEcCtD
Regadenoson—Cardiac arrest—Doxorubicin—peripheral nervous system neoplasm	0.000748	0.000996	CcSEcCtD
Regadenoson—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000745	0.000992	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000741	0.000987	CcSEcCtD
Regadenoson—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.00074	0.000985	CcSEcCtD
Regadenoson—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000739	0.000984	CcSEcCtD
Regadenoson—Nausea—Melphalan—peripheral nervous system neoplasm	0.000739	0.000984	CcSEcCtD
Regadenoson—Asthma—Epirubicin—peripheral nervous system neoplasm	0.000735	0.000978	CcSEcCtD
Regadenoson—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000731	0.000973	CcSEcCtD
Regadenoson—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000728	0.000969	CcSEcCtD
Regadenoson—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000727	0.000969	CcSEcCtD
Regadenoson—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000725	0.000966	CcSEcCtD
Regadenoson—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000724	0.000964	CcSEcCtD
Regadenoson—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000721	0.000959	CcSEcCtD
Regadenoson—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000716	0.000953	CcSEcCtD
Regadenoson—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000705	0.000938	CcSEcCtD
Regadenoson—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000704	0.000937	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000702	0.000935	CcSEcCtD
Regadenoson—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000697	0.000927	CcSEcCtD
Regadenoson—Pain—Cisplatin—peripheral nervous system neoplasm	0.000696	0.000926	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	0.000686	0.0029	CbGpPWpGaD
Regadenoson—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000685	0.000912	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000684	0.000911	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000682	0.00289	CbGpPWpGaD
Regadenoson—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.00068	0.000905	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	0.000678	0.00287	CbGpPWpGaD
Regadenoson—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000678	0.000903	CcSEcCtD
Regadenoson—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.00067	0.000893	CcSEcCtD
Regadenoson—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000669	0.000891	CcSEcCtD
Regadenoson—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000665	0.000885	CcSEcCtD
Regadenoson—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000663	0.000882	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000662	0.000882	CcSEcCtD
Regadenoson—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00066	0.000879	CcSEcCtD
Regadenoson—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000655	0.000872	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000654	0.00277	CbGpPWpGaD
Regadenoson—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000653	0.00087	CcSEcCtD
Regadenoson—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000649	0.000865	CcSEcCtD
Regadenoson—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000644	0.000857	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000644	0.000857	CcSEcCtD
Regadenoson—Pain—Etoposide—peripheral nervous system neoplasm	0.000637	0.000849	CcSEcCtD
Regadenoson—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000631	0.000841	CcSEcCtD
Regadenoson—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00063	0.000838	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—CASP3—peripheral nervous system neoplasm	0.000622	0.00264	CbGpPWpGaD
Regadenoson—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000614	0.000818	CcSEcCtD
Regadenoson—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000612	0.000815	CcSEcCtD
Regadenoson—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00061	0.000812	CcSEcCtD
Regadenoson—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000608	0.00081	CcSEcCtD
Regadenoson—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000607	0.000808	CcSEcCtD
Regadenoson—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000602	0.000802	CcSEcCtD
Regadenoson—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000602	0.000801	CcSEcCtD
Regadenoson—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000599	0.000798	CcSEcCtD
Regadenoson—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000599	0.000797	CcSEcCtD
Regadenoson—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000598	0.000797	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000596	0.000793	CcSEcCtD
Regadenoson—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000592	0.000788	CcSEcCtD
Regadenoson—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000589	0.000785	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000585	0.000779	CcSEcCtD
Regadenoson—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000585	0.000779	CcSEcCtD
Regadenoson—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000584	0.000777	CcSEcCtD
Regadenoson—Rash—Vincristine—peripheral nervous system neoplasm	0.00058	0.000772	CcSEcCtD
Regadenoson—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00058	0.000772	CcSEcCtD
Regadenoson—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000578	0.000769	CcSEcCtD
Regadenoson—Headache—Vincristine—peripheral nervous system neoplasm	0.000576	0.000768	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000572	0.00242	CbGpPWpGaD
Regadenoson—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000567	0.000755	CcSEcCtD
Regadenoson—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000557	0.000741	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000554	0.000738	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.00055	0.000732	CcSEcCtD
Regadenoson—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000549	0.000731	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000548	0.00073	CcSEcCtD
Regadenoson—Nausea—Vincristine—peripheral nervous system neoplasm	0.000547	0.000728	CcSEcCtD
Regadenoson—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000546	0.000727	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000546	0.000727	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000541	0.000721	CcSEcCtD
Regadenoson—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000535	0.000712	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000535	0.000712	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000534	0.00071	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000531	0.000707	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00053	0.000706	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000529	0.00224	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NRAS—peripheral nervous system neoplasm	0.000522	0.00221	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000519	0.0022	CbGpPWpGaD
Regadenoson—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000517	0.000689	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000517	0.00219	CbGpPWpGaD
Regadenoson—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000515	0.000686	CcSEcCtD
Regadenoson—Rash—Cisplatin—peripheral nervous system neoplasm	0.000513	0.000683	CcSEcCtD
Regadenoson—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000513	0.000682	CcSEcCtD
Regadenoson—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000512	0.000682	CcSEcCtD
Regadenoson—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00051	0.000679	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000509	0.000677	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000507	0.000676	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000505	0.000672	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000505	0.000672	CcSEcCtD
Regadenoson—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000501	0.000668	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.0005	0.00212	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	0.000496	0.0021	CbGpPWpGaD
Regadenoson—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000494	0.000657	CcSEcCtD
Regadenoson—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000493	0.000656	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000492	0.000654	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00049	0.000653	CcSEcCtD
Regadenoson—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000483	0.000643	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000482	0.000642	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000477	0.00202	CbGpPWpGaD
Regadenoson—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000477	0.000635	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000475	0.000632	CcSEcCtD
Regadenoson—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000474	0.000631	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000474	0.000631	CcSEcCtD
Regadenoson—Rash—Etoposide—peripheral nervous system neoplasm	0.00047	0.000626	CcSEcCtD
Regadenoson—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.00047	0.000625	CcSEcCtD
Regadenoson—Headache—Etoposide—peripheral nervous system neoplasm	0.000467	0.000622	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000464	0.000618	CcSEcCtD
Regadenoson—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000462	0.000615	CcSEcCtD
Regadenoson—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000459	0.000611	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000454	0.00192	CbGpPWpGaD
Regadenoson—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000452	0.000602	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.00045	0.000599	CcSEcCtD
Regadenoson—Cough—Epirubicin—peripheral nervous system neoplasm	0.000447	0.000595	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000446	0.000594	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000444	0.000591	CcSEcCtD
Regadenoson—Nausea—Etoposide—peripheral nervous system neoplasm	0.000443	0.00059	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000442	0.000589	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.00044	0.000585	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	0.000438	0.00186	CbGpPWpGaD
Regadenoson—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000436	0.00058	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000436	0.00058	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000436	0.00058	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000434	0.000578	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000433	0.000576	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000431	0.000573	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000427	0.000569	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000425	0.000566	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000419	0.000557	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000418	0.000556	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000416	0.000554	CcSEcCtD
Regadenoson—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000413	0.00055	CcSEcCtD
Regadenoson—Shock—Epirubicin—peripheral nervous system neoplasm	0.000411	0.000547	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.00041	0.000546	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.00041	0.000546	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000409	0.000545	CcSEcCtD
Regadenoson—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000408	0.000543	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000406	0.00054	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000404	0.000538	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000403	0.000537	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000403	0.000537	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000403	0.000537	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000402	0.000535	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000401	0.000533	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000398	0.000531	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.00039	0.00052	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000387	0.000515	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—HRAS—peripheral nervous system neoplasm	0.000382	0.00162	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000381	0.000507	CcSEcCtD
Regadenoson—Shock—Doxorubicin—peripheral nervous system neoplasm	0.00038	0.000506	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000379	0.000505	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000378	0.000503	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000377	0.000502	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000376	0.0005	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000375	0.0005	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000374	0.000498	CcSEcCtD
Regadenoson—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000373	0.000496	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000371	0.000495	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000361	0.000481	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000361	0.00048	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000358	0.00152	CbGpPWpGaD
Regadenoson—Pain—Epirubicin—peripheral nervous system neoplasm	0.000357	0.000476	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000352	0.000469	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.00035	0.000466	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000462	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.000459	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000344	0.000458	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000344	0.000458	CcSEcCtD
Regadenoson—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000342	0.000455	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—peripheral nervous system neoplasm	0.000337	0.00143	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.000444	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000332	0.000442	CcSEcCtD
Regadenoson—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000331	0.00044	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.00033	0.00044	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000319	0.000424	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000316	0.000421	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000315	0.00134	CbGpPWpGaD
Regadenoson—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000308	0.00041	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000307	0.000409	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000307	0.0013	CbGpPWpGaD
Regadenoson—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000306	0.000407	CcSEcCtD
Regadenoson—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.0003	0.000399	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000292	0.00124	CbGpPWpGaD
Regadenoson—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000286	0.000381	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.000379	CcSEcCtD
Regadenoson—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000277	0.000369	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000276	0.000368	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000268	0.00114	CbGpPWpGaD
Regadenoson—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000266	0.000354	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000265	0.000352	CcSEcCtD
Regadenoson—Rash—Epirubicin—peripheral nervous system neoplasm	0.000263	0.000351	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000263	0.00035	CcSEcCtD
Regadenoson—Headache—Epirubicin—peripheral nervous system neoplasm	0.000262	0.000349	CcSEcCtD
Regadenoson—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.00034	CcSEcCtD
Regadenoson—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000248	0.00033	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000246	0.000327	CcSEcCtD
Regadenoson—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.000325	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.000324	CcSEcCtD
Regadenoson—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.000322	CcSEcCtD
Regadenoson—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.00023	0.000306	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.00019	0.000803	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000186	0.000789	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000147	0.000624	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	0.000139	0.000588	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	0.000135	0.000571	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	0.000134	0.000566	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	0.000122	0.000519	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000112	0.000475	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	0.000104	0.000442	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.57e-05	0.000363	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.2e-05	0.000347	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.24e-05	0.000307	CbGpPWpGaD
